Last reviewed · How we verify
A Clinical Study to Evaluate Symbicort Turbuhaler Used 'as Needed' in Adults and Adolescents With Asthma. (SYGMA1)
The purpose of this study is to test if Symbicort® (budesonide/formoterol) Turbuhaler® is effective in treating asthma when used 'as needed' in patients with milder asthma. The efficacy of Symbicort® 'as needed' will be compared with: 1) terbutaline Turbuhaler® 'as needed' and with 2) Pulmicort (budesonide) Turbuhaler® twice daily plus terbutaline Turbuhaler® 'as needed'.
Details
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 3850 |
| Start date | Mon Jul 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed Aug 02 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Asthma
Interventions
- budesonide/formoterol 'as needed' + budesonide placebo bid
- terbutaline 'as needed' + placebo budesonide bid
- budesonide bid + terbutaline 'as needed'
Countries
South Africa, Russia, Ukraine, Peru, Chile, United Kingdom, Vietnam, Hungary, Mexico, Philippines, Poland, Romania, Canada, South Korea, Bulgaria, Australia, China, Brazil